ER-Positive Metastatic Breast Cancer — An Interview with Prof Patrick Neven on the Role of Oral Selective Estrogen Receptor Degraders (Companion Faculty Lecture)

Featuring a slide presentation and related discussion from Prof Patrick Neven, including the following topics:

• Biology of the estrogen receptor (ER) and mechanisms of resistance to therapy (0:00)
• Clinical trial data involving oral selective ER degraders (SERDs) for endocrine-resistant ER-positive, HER2-negative metastatic breast cancer (13:34)
• Utility of switching to an oral SERD before radiographic disease progression for patients receiving first-line endocrine treatment (23:12)
• Ongoing trials with oral SERDs for ER-positive, HER2-negative breast cancer (27:13)
• Case: Patient with ER-positive, HER2-negative breast cancer receives imlunestrant upon disease progression on first-line letrozole (32:34)
• Case: Patient with ER-positive, HER2-negative breast cancer receives imlunestrant/abemaciclib upon relapse on letrozole/abemaciclib (34:16)
• Case: Patient with ER-positive, HER2-negative breast cancer receives camizestrant after first-line tamoxifen (36:20)
• Case: Patient with ER-positive, HER2-negative breast cancer receives elacestrant after disease progression on first-line letrozole/palbociclib (38:11)

CME information and select publications